Literature DB >> 23875623

Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone.

Janice C Froehlich1, Brett J Hausauer, Dennis D Rasmussen.   

Abstract

BACKGROUND: Naltrexone (NTX) is underutilized in clinical treatment settings because its efficacy is modest, and it is not effective for all alcoholics and, when it is effective, a significant number of alcoholics fail to maintain initial treatment gains and subsequently relapse to heavy drinking. This has slowed acceptance of NTX by the treatment community, and there is a clear need for additional treatments for alcoholism and alcohol use disorders. Given that NTX and prazosin can each reduce alcohol drinking in rats selectively bred for alcohol preference and high voluntary alcohol drinking (alcohol-preferring "P" rats), we tested whether a combination of NTX + prazosin is more effective in decreasing alcohol drinking than is either drug alone.
METHODS: P rats were given access to a 15% (v/v) alcohol solution for 2 hours daily. Rats were fed NTX and prazosin, alone or in combination, prior to onset of the daily 2-hour alcohol access period for 4 weeks and the effect of drug treatment on alcohol and water intake was assessed.
RESULTS: During the first week of treatment, neither a low dose of NTX, nor prazosin, was effective in decreasing alcohol intake when each drug was administered alone, but combining the 2 drugs in a single medication significantly reduced alcohol intake. The combination was as effective as was a higher dose of NTX. Using a low dose of NTX in combination with prazosin may reduce the potential for undesirable side effects early in treatment which, in turn, may improve patient compliance and result in a more successful outcome when NTX is used for treating alcoholism and alcohol use disorders.
CONCLUSIONS: Combining low-dose NTX and prazosin in a single medication may be more useful than is either drug alone for treating both inpatient and outpatient alcoholics and heavy drinkers early in the treatment process.
Copyright © 2013 by the Research Society on Alcoholism.

Entities:  

Keywords:  Alcoholism Treatment; Genetic Selection; Naltrexone; Prazosin

Mesh:

Substances:

Year:  2013        PMID: 23875623      PMCID: PMC3795831          DOI: 10.1111/acer.12148

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  49 in total

Review 1.  Animal models for the study of alcoholism: utility of selected lines.

Authors:  J C Froehlich; T K Li
Journal:  J Addict Dis       Date:  1991

2.  Progress toward a voluntary oral consumption model of alcoholism.

Authors:  T K Li; L Lumeng; W J McBride; M B Waller
Journal:  Drug Alcohol Depend       Date:  1979 Jan-Mar       Impact factor: 4.492

3.  Estimation of area under the curve for drugs subject to enterohepatic cycling.

Authors:  T A Shepard; R H Reuning; L J Aarons
Journal:  J Pharmacokinet Biopharm       Date:  1985-12

4.  Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.

Authors:  H R Kranzler; J Van Kirk
Journal:  Alcohol Clin Exp Res       Date:  2001-09       Impact factor: 3.455

5.  Disulfiram treatment of alcoholism. A Veterans Administration cooperative study.

Authors:  R K Fuller; L Branchey; D R Brightwell; R M Derman; C D Emrick; F L Iber; K E James; R B Lacoursiere; K K Lee; I Lowenstam
Journal:  JAMA       Date:  1986-09-19       Impact factor: 56.272

6.  Naltrexone and dysphoria: a double-blind placebo controlled trial.

Authors:  R Malcolm; P M O'Neil; J M Von; P C Dickerson
Journal:  Biol Psychiatry       Date:  1987-06       Impact factor: 13.382

7.  Salt-sensitive hypertension caused by long-term alpha-adrenergic blockade in the rat.

Authors:  J W Osborn; B J Provo; J S Montana; K A Trostel
Journal:  Hypertension       Date:  1993-06       Impact factor: 10.190

8.  Aversive effects of naltrexone in subjects not dependent on opiates.

Authors:  L E Hollister; K Johnson; D Boukhabza; H K Gillespie
Journal:  Drug Alcohol Depend       Date:  1981-08       Impact factor: 4.492

9.  Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference.

Authors:  J C Froehlich; J Harts; L Lumeng; T K Li
Journal:  Pharmacol Biochem Behav       Date:  1990-02       Impact factor: 3.533

10.  [Role of alpha 1 adrenergic receptors in water balance in the rat].

Authors:  A Auriac; J Azam; J C Dumas; G Roux; J L Montastruc
Journal:  J Pharmacol       Date:  1983 Jul-Sep
View more
  28 in total

1.  Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone.

Authors:  Yan Zhou; Rachel Saylor Crowley; Konrad Ben; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  Brain Res       Date:  2017-03-02       Impact factor: 3.252

2.  Evaluation of the effect of doxasozin and zonisamide on voluntary ethanol intake in mice that experienced chronic intermittent ethanol exposure and stress.

Authors:  Marcelo F Lopez; Sarah E Reasons; Benjamin A Carper; Tracy L Nolen; Rick L Williams; Howard C Becker
Journal:  Alcohol       Date:  2020-07-24       Impact factor: 2.405

3.  Effects of cannabidiol plus naltrexone on motivation and ethanol consumption.

Authors:  Adrián Viudez-Martínez; María S García-Gutiérrez; Ana Isabel Fraguas-Sánchez; Ana Isabel Torres-Suárez; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-07-01       Impact factor: 8.739

4.  Naltrexone and prazosin combination for posttraumatic stress disorder and alcohol use disorder.

Authors:  Hamid Qazi; Heshan Wijegunaratne; Ravi Savajiyani; Maju Mathew Koola
Journal:  Prim Care Companion CNS Disord       Date:  2014-08-21

5.  Prazosin Reduces Alcohol Intake in an Animal Model of Alcohol Relapse.

Authors:  Janice C Froehlich; Brett Hausauer; Stephen Fischer; Bradley Wise; Dennis D Rasmussen
Journal:  Alcohol Clin Exp Res       Date:  2015-08       Impact factor: 3.455

6.  Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol-Preferring (P) Rats.

Authors:  Janice C Froehlich; Emily R Nicholson; Julian E Dilley; Nick J Filosa; Logan C Rademacher; Teal N Smith
Journal:  Alcohol Clin Exp Res       Date:  2017-07-10       Impact factor: 3.455

Review 7.  Combined pharmacotherapies for the management of alcoholism: rationale and evidence to date.

Authors:  Mary R Lee; Lorenzo Leggio
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

Review 8.  A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.

Authors:  R L Bell; S Hauser; Z A Rodd; T Liang; Y Sari; J McClintick; S Rahman; E A Engleman
Journal:  Int Rev Neurobiol       Date:  2016-03-21       Impact factor: 3.230

9.  Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism.

Authors:  Janice C Froehlich; Stephen M Fischer; Julian E Dilley; Emily R Nicholson; Teal N Smith; Nick J Filosa; Logan C Rademacher
Journal:  Alcohol Clin Exp Res       Date:  2016-07-29       Impact factor: 3.455

Review 10.  Influence of stress associated with chronic alcohol exposure on drinking.

Authors:  Howard C Becker
Journal:  Neuropharmacology       Date:  2017-04-19       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.